The psychiatrist used to have to stay with the patient during their entire session. Now they’ll be able to leave the room after administering the drug.
Articles on Psychedelics therapy
Displaying all articles
Doctors working in palliative care see promise in emerging therapies involving psychedelic drugs, but say many questions still need to be addressed.
Psilocybin falls into a regulatory gray zone, with strict limitations around how it can be studied. As a result, very little is known about its health risks, despite its surging popularity.
Studies show psilocybin therapy can rapidly reduce anxiety and depression in terminally ill patients, but UK regulations make access nearly impossible.
Top contributors
-
Professor, Law, Medicine and Technology, University of Birmingham
-
Research Fellow, Law, University of Birmingham
-
Professor of Psychopharmacology, University of Manchester
-
Professor of Psychiatry, University of Colorado Anschutz
-
Associate Professor of Psychiatry, University of Colorado Anschutz
-
Associate Professor in Psychological Medicine, University of Auckland, Waipapa Taumata Rau
-
Adjunct Clinical Associate Professor, Eastern Health Clinical School, Monash University; Curtin University
-
Professor and Deputy Director, Monash Addiction Research Centre, Monash University
-
NHMRC Postgraduate Scholar and Fulbright Alumna in Public Health Policy, Monash University